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Abstract
We report theﬁrst investigation into the bioprinting of human induced pluripotent stem cells
(hiPSCs), their response to a valve-based printing process as well as their post-printing differentiation
into hepatocyte-like cells (HLCs). HLCs differentiated fromboth hiPSCs and human embryonic stem
cells (hESCs) sources were bioprinted and examined for the presence of hepaticmarkers to further
validate the compatibility of the valve-based bioprinting process with fragile cell transfer. Examined
cells were positive for nuclear factor 4 alpha andwere demonstrated to secrete albumin and have
morphology that was also found to be similar to that of hepatocytes. Both hESC and hiPSC lines were
tested for post-printing viability and pluripotency andwere found to have negligible difference in
terms of viability and pluripotency between the printed and non-printed cells. hESC-derivedHLCs
were 3Dprinted using alginate hydrogelmatrix and tested for viability and albumin secretion during
the remaining differentiation andwere found to be hepatic in nature. 3Dprintedwith 40-layer of
HLC-containing alginate structures reached peak albumin secretion at day 21 of the differentiation
protocol. This work demonstrates that the valve-based printing process is gentle enough to print
humanpluripotent stem cells (hPSCs) (both hESCs and hiPSCs)while eithermaintaining their
pluripotency or directing their differentiation into speciﬁc lineages. The ability to bioprint hPSCswill
pave theway for producing organs or tissues on demand frompatient speciﬁc cells which could be
used for animal-free drug development and personalizedmedicine.
1. Introduction
New drug development can take 10 to 20 years with
an estimated average of about 9 to 12 years [1, 2]. In
addition, only around 16% of the drugs that begin
preclinical testing are approved for human use [3].
Some of this low success rate can be attributed to the
different responses that animals and humans have to
the drugs being tested; some drugs have to be with-
drawn from market due to toxic effects on human
organs such as liver and heart, despite being tested
safely on animals. A possible solution to this might be
the creation of human pluripotent stem cell (hPSC)
-derived micro-tissues which could be used with
organ-on-a-chip devices [4–7]. These micro-tissues
are expected to produce the same or similar physiolo-
gical reaction that the entire organ would but on a
much smaller scale. This would result in scalable,
faster and potentially more reliable drug testing
platform, and hopefully an end to animal testing.
hPSCs are the ideal cells to use for this application
due to their ability to self-renew indeﬁnitely, which
enables large populations of cells to be created easily
in vitro, and their pluripotency which means that they
OPEN ACCESS
RECEIVED
15April 2015
REVISED
15 June 2015
ACCEPTED FOR PUBLICATION
24 June 2015
PUBLISHED
21October 2015
Content from this work
may be used under the
terms of theCreative
CommonsAttribution 3.0
licence.
Any further distribution of
this workmustmaintain
attribution to the
author(s) and the title of
thework, journal citation
andDOI.
©2015 IOPPublishing Ltd
can be differentiated into any required adult cell type
[8–13]. Pluripotent stem cells can be divided into
embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs). Human ESCs (hESCs) were ﬁrst
isolated from early human blastocysts in 1998 [14].
Any tissue construct created fromhESCs for implanta-
tion in vivo would require the patient to receive
immunosuppressive drugs and ethical issues still
restrict some applications due to their source. iPSCs
have neither of these drawbacks as they can be created
from harvested adult cells from the patient requiring
treatment and as such any implanted cells derived
from these iPSCs should not be rejected by the
patient’s immune system but may require immuno-
suppressive drugs at a greatly reduced dosage. In 2006
Shinya Yamanaka discovered that iPSCs can be
derived from somatic cells by
retrovirally transducing them with four transcription
factors—Oct3/4, Sox2, Klf4 and C-myc [15, 16].
These cells have the same self-renewal and differentia-
tion capabilities as ESCs but with the added advantage
that iPSCs can be used for autologous therapies.
These unique characteristics make pluripotent stem
cells ideal for use in a number of applications such as
clinical tissue engineering, novel drug discovery and
testing for the pharmaceutical industry [8, 9, 17, 18].
In the ﬁeld of biofabrication, great advances are
being made towards fabricating 3D tissue and organs
with very ﬁne spatial control of cell deposition. From
the very ﬁrst paper that was published investigating
printing of biological cells (or bioprinting), tissue
engineering was identiﬁed as a major application for
this new technology [19]. If more complex structures
such as organs and tissues were to be printed, the bio-
printer would need the ability to transfer microscopic
patterns of viable cells of multiple cell types into well-
deﬁned three-dimensional arrays that closely mimic
the tissue structure. There has been much progress in
the development and establishment of several differ-
ent bioprinting techniques for 3D live constructs [20–
22] including those based on laser pulses, inkjets and
other more novel approaches. It is an inescapable fact
that cells will be subjected to some level of stress dur-
ing deposition, regardless of the printing technique
being used. For example, cells printed by non-contact
methods will be affected when they impact on the sub-
strate at some incident velocity, which would result in
extreme deceleration and shear stress [23–26]. Shear
stress is applied to cells pushed through nozzle oriﬁces
and capillary tubes [24, 27–42] and the actuation is
provided via pressure, heat, or high frequency vibra-
tion which can also be damaging to the cells
[30, 31, 43–46]. If cells are exposed to laser energy the
radiation can cause genetic damage [29, 47–54] and
shear forces are applied during cavitation and jet for-
mation [23, 55]. Ultrasonic actuation for cell transfer
would subject the cells to stress in the form of heat and
vibration [56, 57]. Therefore, it is important to validate
the response of printed cells to any particular
bioprinting process in terms of their viability and
more importantly their biological functions.
We previously reported the results of the ﬁrst
experiments printing hESCs using a valve-based print-
ing approach including their response to the printing
process in the form of post-printed viability and plur-
ipotency validation [37]. However, if hPSCs are to be
used for producing human tissues on demand for drug
testing, their post-printing differentiation must be
reproducibly directed to the required lineages for each
tissue. Unfortunately homogenous cellular differ-
entiation of hPSCs into some germ layers has proved
difﬁcult [12, 13]. Here, we report the ﬁrst investigation
into the bioprinting of human iPSCs, their response to
the valve-based printing process as well as their post-
printing differentiation into hepatocyte-like cells
(HLCs). HLCs that are in the process of differentiating
are bioprinted and examined to further validate the
compatibility of the valve-based bioprinting process
with fragile cell transfer. Finally, 3D hydrogel struc-
tures were designed and printed out with encapsulated
hESC-derived HLCs and the viability and hepatic
characteristics of the cells were investigated.
2.Materials andmethods
2.1. Cell culture
Human induced pluripotent stem (hiPS) cell lines
RCi-22 and RCi-50 and hESC lines RC-6 and RC-10
were supplied by Roslin Cells Ltd for this research.
The hiPS cells were cultured on Geltrex matrix
with Essential 8 medium (Life Technologies) and
the hES cells were cultured in complete StemPro®
hESC serum-and feeder-free medium (SFM) (supple-
ment, DMEM/F-12, BSA, FGF basic, and
2-mercaptoethanol) (Life Technologies) supplemen-
ted with 8 ng mL−1 of human basic ﬁbroblast growth
factor. Cells were cultured in a laboratory incubator
set at 36.0 °C–37.5 °C, 5.0%±0.5%CO2.
2.2. Cell printing platform
A newer version of our previously reported cell
printing platform [37] has been developed. Four
nanolitre dispensing systems, each comprising a
solenoid valve (VHS Nanolitre Dispense Valve, Lee
Products Ltd)with 101.6 μminternal diameter nozzles
(Minstac Nozzle, Lee Products Ltd), were attached to
static pressure reservoirs for the bio-ink solution to be
dispensed from via ﬂexible tubing. The nanolitre
dispensing system and bio-ink reservoirs were
mounted onto the tool head of an enclosed custom
built micrometer-resolution 3-axis XY–Z stage
(ﬁgure 1). This newer cell printing platform improved
on the previous version by reducing the overall
size and weight of the machine, allowing it to be
mounted inside a standard tissue culture hood during
experiments requiring a sterile environment. Other
enhancements included the two extra nanolitre
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dispensing systems, taking the total up to four, a more
robust electronics and custom ﬁrmware was devel-
oped which improved the reliability and speed of the
machine and two separate pressure channels were
included, allowing for differential bio-ink dispensing
conditions. Unless otherwise stated standard printing
conditions were used: for 2D, printing was carried out
using a pulse time of 8 ms at an inlet pressure of 0.6 bar
using a nozzle with an internal diameter of 101.6 μm;
for 3D, printing was carried out using a pulse time of
400 μs at an inlet pressure of 1.0 bar for sodium
alginate solution and a pulse time of 400 μs at an inlet
pressure of 0.5 bar for calcium chloride solution both
using nozzles with an internal diameter of 101.6 μm.
2.3. Bioprinter sterilization and validation
The bioprinting systemwas sterilized and rinsedwith a
2% solution of Presept (Johnson and Johnson
Medical) (left to stand for 30 min), a 70% solution of
Ethanol and water (all micro-ﬁltered), then Tryptose
Phosphate broth (Sigma-AldrichCo. LLC)was printed
into the wells of a 96-well plate for testing. The plate
was incubated in a CO2 incubator (Galaxy S+, RS
Biotech) at 36.0 °C–37.5 °C, 5.0%±0.5% CO2 and
checked formicrobial growth every 72 h for 21 d.
2.4. Cell viability
Human ES cells (line RC-10) were suspended in
StemPro® hESC SFM to a concentration of approxi-
mately 1×106 cells/mL, loaded into the reservoir
of one of the cell deposition systems and dispensed
in approximately 1 mL increments of bio-ink (the
volume varied with pressure) using a previously
written program; this large volume was required to
allow for analysis to be carried out on a ﬂuorescence-
activated cell sorting (FACS)ﬂow cytometer.
Figure 1. (a) Schematic drawing of the cell printer system; (b) detailed schematic of themicro-solenoid valve; (c) schematic of the
combinatorial printing process for alginate hydrogel creation; (d) a 3Dprinted alginate tube structure approximately 13 mm tall
printedwith 1.5%w/v SodiumAlginate and 600 mM (6%)CalciumChloride solutions inMilliporewater (scale bar 2 mm).
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Different experiments sometimes require different
experimental variables such as applied pressure and
nozzle geometry. Two main types of nozzle have been
used for the experiments: a shorter, thick-walled noz-
zle; and a longer, thin-walled nozzle. The shorter noz-
zle measured 8.9 mm in length while the longer nozzle
measured 24.4 mm. Since such a large volume was
required for each pressure/nozzle combination, only
four different pressures were used to limit the number
of cells required for this experiment. Cells were prin-
ted into micro-centrifuge tubes and the unprinted
cells were used as a control.
The printed samples were examined using a BD
FACSCalibur ﬂow cytometer (BDCell Viability Kit) at
approximately 30 min post printing. The control sam-
ple was split in two; half was used to calibrate the data
thresholds.
Human iPS cells (line RCi-22) viability was mea-
sured in much the same way as the hESC viability but
without a variation in nozzle geometry or pressures.
The printed samples were examined using the ﬂow
cytometer.
2.5.Multi-marker pluripotency validation hESC
(RC-10) and human induced pluripotent stem cells
(hiPSC) (RCi-22)
Cells were printed directly into the wells of 12-well
plates and cultured in a CO2 incubator (Galaxy S+, RS
Biotech) at 36.0 °C–37.5 °C, 5.0%±0.5% CO2 for
one week. The now adherent hPSCs were washed once
with PBS and Tryple select (Invitrogen) was added to
detach the cells from the surface and return them to a
single cell suspension. A sample was viewed under the
microscope to conﬁrm the presence of single cells.
Cells were then washed three times with PBS and
centrifuged at 300 g for 5 min before being re-
suspended in an appropriate volume of PBS for the
required cell concentration.
Cells were ﬁxed using BD Cytoﬁx™ for 20 min at
room temperature (RT). Cells were permeabilised by
washing twice with 1X BD Perm/Wash buffer (cen-
trifuging at 500 g for 5 min), re-suspended in 1X BD
Perm/Wash buffer at 1×107 cells/mL and then
incubated for 10 min at RT.
Printed and control samples were analyzed using a
FACS machine (FACSCalibur, BD) according to the
BD human and mouse pluripotent stem cell analysis
protocol.
2.6.Directed differentiation of hPSCs intoHLCs
We used a modiﬁed version of the three-step protocol
devised by Hay et al [13] to direct the differentiation of
hPSCs intoHLCs; this protocol is shown in ﬁgure 2. In
brief, cells are seeded at a speciﬁc initial concentration
in StemPro® hESC SFM, after 24 h this medium was
replaced with RPMI-B27 medium (Invitrogen) and
the hESCs were treated with Activin A andWnt 3a for
3 d. Following this, the cells were cultured in serum
replacement medium (SR/DMSO: knockout-Dulbec-
co’s modiﬁed Eagle’s medium containing 20% SR,
1 mm Glutamine, 1% non essential Amino Acids,
0.1 mM ß-Mercaptorthanol, and 1% DiMethyl Sulf-
oxide [DMSO]) for 5 d. For the ﬁnal maturation step
cells were cultured in L15medium supplemented with
8.3% Fetal Bovine Serum, 8.3% Tryptose Phosphate
broth, 10 μMHydocortisone 21-hemisuccinate, 1 μM
Insulin, and treated with 10 ng mL−1 Hepatocyte
Growth Factor and 20 ng mL−1OncostatinM for 9 d.
2.7.HNF4α and albumin Immunoﬂuorescence
The cells should be positive for hepatocyte nuclear
factor 4 alpha (HNF4α) if they have started differen-
tiating into hepatocytes. As the cells mature they
should begin to express albumin, which can only be
synthesized in large quantities by mature hepatocytes
(immature hepatocytes also express albumin but at
much lower levels) [13, 58]. On completion of the
differentiation process, cells were washed in PBS and
ﬁxed using 4% Paraformaldehyde for 20 min at RT.
Cells were permeabilised by washing in PBST (PBS
plus 0.1% Tween20) and blocked using 10% normal
goat serum (NGS) (G9023, Sigma-Aldrich Co. LLC) in
PBST for 1 h at RT. Blocking buffer was then replaced
using antibody diluent buffer (1% NGS) and the
appropriate primary antibody. HNF4α rabbit poly-
clonal IgG (SC8987, Santa Cruz Biotechnology Inc.) at
a dilution of 1:100 or human serum albumin IgG2a
mouse monoclonal (A6684, Sigma-Aldrich Co. LLC)
at a dilution of 1:500 or ZO-1 IgG rabbit polyclonal
(SC10804, SantaCruz Biotechnology Inc.) at a dilution
of 1:50. This was incubated overnight at 2 °C–8 °C.
Primary antibodywas removed bywashing three times
with PBST for 5 min each at RT. Secondary antibodies
for HNF4α and ZO-1- goat anti rabbit IgG (ab96884,
Abcam plc.) and human serum albumin-goat anti
mouse IgG (A11029, Life Technologies) were diluted
1:200 in PBST and were used for 1 h at RT in the dark
on a rocker table. Unbound antibody was removed
during three 5 min PBS washes on a rocker table at RT
in the dark. Samples were then counterstained using
DAPI before being analyzed on a ﬂuorescence
microscope.
2.8. Albumin ELISA
Cell culture supernatants were collected from non-
printed control and 3D bioprinted structures on day
12,16,19,21 and 23 of the differentiation process.
Albumin secretionwas detected and quantiﬁed using a
human albumin ELISA (ab108788, Abcam plc.) used
according tomanufacturer’s instructions.
2.9. 3Dbioprinting using alginate hydrogel
Alginate is a natural linear polysaccharide copolymer
which is extracted from brown seaweed algae. Due to
their biocompatibility, non-immunogenicity, low
toxicity and hydrophilic nature, alginate hydrogels
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have many attractive features for biomedical applica-
tions [59]. The mechanical properties of a gelled
alginate solution, including viscosity and overall stiff-
ness, depend on the concentration of the polymer and
its molecular weight distribution [60, 61]. Crosslink-
ing between the polymer chains depends on the
amount of polymer chains and multivalent cations
(e.g. Ca2+, Ba2+) present in the solution and the
temperature [59–62]. In vitro, alginates typically
degrade by approximately 40%within 9 d; this is most
likely due to the diffusion of ions into the surrounding
medium [63].
RGD-coupled sodium alginate (NOVATACH
GRGDSP, Novamatrix), Calcium chloride dihydrate
(223506, Sigma-Aldrich Co. LLC), and Barium chlor-
ide (B0750, Sigma-Aldrich Co. LLC) were used to
form alginate hydrogels. RGD-coupled alginate was
used for its known bio-compatibility with stem cells
[64]. Alginate hydrogel structures are bioprinted by
dispensing an array of droplets of alginate solution
from the left nozzle and then overprinting droplets of
calcium solution from the right. After a few seconds
the alginate chains bond with the calcium ions to form
a hydrogel matrix. If adjacent droplets overlap they gel
together and form a single continuous layer. Addition-
ally, by exposing the printed hydrogel structures to
barium chloride the structural integrity will increase.
5×106 hESC-HLCs at day 6 of the differentiation
protocol were suspended in 0.5 mL 1.5% w/v sodium
alginate resulting in a concentration of 1×107 cells/
mL−1. 60 mM calcium chloride was used as the cross-
linker. Programs describing 3D ring structures with a
range of layer heights and diameters were created for
the bioprinter. These ring structures were then printed
out using the HLC-laden alginate into the wells of
12-well plate. After printing, the cell laden hydrogel
structures were exposed to barium chloride (55 mM)
for 2 min Differentiation media was then added to
the printed structures and the cells were allowed to
continue their differentiation to day 17 suspended in
the alginate. The plates were incubated in a CO2 incu-
bator (Galaxy S+, RS Biotech) at 36.0 °C–37.5 °C,
5.0%±0.5% CO2. At day 17 a number of structures
were dissociated using 55 mM EDTA to allow for
examination of hepaticmarkers.
2.10. 3D imaging and viabilitymeasurement
Confocal laser scanning microscopy (CLSM) (Leica
SP5 SMD; Leica microsystems)was used for 3D image
acquisition. Images were taken using a dry 20X
objective. CLSM images were analyzed using Imaris
(Bitplane, AG) software to investigate the viability of
the bioprinted cells post-printing and end of the
differentiation process.
3. Results and discussion
3.1. Bioprinter sterilization and validation
Producing human tissue from pluripotent stem cells
requires the printed samples to be cultured post-
printing for several weeks to allow the cells to
differentiate into the required lineages. Creation of
tissue from stem cells using bioprinting techniques
usually involve a lengthy culture periods which can
last from several weeks up to months in some cases
[65–67], so it was important to ensure that not only
would these cells be unaffected by the printing process
but that no microbial contamination entered the
system and affected the results. Therefore the bioprin-
ter was thoroughly cleaned, placed in a Class II
microbiological safety cabinet and tested for sterility
using Tryptose Phosphate broth. The broth-populated
plate was removed from the incubator and examined
at three day intervals up to 21 d post-printing and
there was no evidence of microbial contamination
present therefore the system was deemed to be sterile.
Sterilization is essential for long term culture and as
the differentiation protocol forHLCs lasts for 17 d, it is
crucial that the printer does not introduce foreign
contaminants into the culture environment which
might inﬂuence the differentiation of the stem cells.
Even without the use of antibiotics, samples printed
using our bioprinting system remained sterile for at
least threeweeks.
Figure 2.A schematic representation of the three-step protocol used to differentiate hPSCs intoHLCs detailing themedia changes and
treatments required for each stage.
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3.2. The effect of pressure and nozzle length on
hESCviability
We previously demonstrated that hESCs bioprinted
using valve-based techniques retain high viability
post-printing using trypan blue exclusion [37]. Here,
we further conﬁrm this result by carrying out a more
systematic study using FACS, which yields more
statistically signiﬁcant results to the previous study,
and expand the study by examining the effect of
different nozzle lengths on post-printed viability of
hESCs. Other groups have previously examined the
effects of nozzle diameter on cell viability [68–71], but
the effect of nozzle length on cell viability has not been
investigated. The two nozzles used in this study
measured 8.9 and 24.4 mm in length. The graph of the
results is shown in ﬁgure 3. These results clearly show
that increased pressure results in lower cellular viabi-
lity; this can be attributed to the higher shear forces
applied to the cells as they are printed. However cell
viability remains high at pressures below 1 bar even for
sensitive cells such as hESCs, which is consistent with
the observations of other groups with stem cells [72]
and other cell types using similar bioprinting
approaches [68, 69].
Cell viability was calculated to be >84% for the
short nozzle and >71% for the long nozzle over all
pressures. This clearly shows that the viability of the
cells is affected by the length of the nozzle used; this
is most likely due to the increased time the cells are
subject to shear forces through the nozzle. We spec-
ulate that the higher viability of hESCs (RC-10 in
this case) post-printing as compared to the non-
printed control might be due to printing induced
homogenizing of the cell suspensions; live hESCs
tend to aggregate into small clumps which could be
falsely identiﬁed as single cells in control solutions
but be broken up during printing and counted
separately.
3.3. hPSC viability post printing
Using the results shown in ﬁgure 3, the optimal
printing conditions were set at 0.6 bar and the shorter
nozzlewas used.Using these parameters, we compared
the viability of hESC andhiPSCpost printing. The data
plots and a graph of the results are shown in ﬁgure 4.
There is negligible difference in terms of viability
between the printed and non-printed hiPSCs and
there is actually an increase in viability between the
printed and non-printed hESCs which shows that our
valve-based printing technology is compatible with
hPSC transfer without affecting the viability of these
fragile cells.
3.4.Multi-marker pluripotency validation
Viability alone is insufﬁcient when printing pluripo-
tent stem cells; printed cells must not only be viable
but also morphologically unchanged by the printing
process. In other words, they need to still be pluripo-
tent stem cells post-printing; the bioprinting process
must not trigger the cells to differentiate. Pluripotency
can be validated by testing cells for the presence of
certain biomarkers including SSEA-3, SSEA-4,
OCT3/4, SOX2, NANOG and many others [15, 73].
The printed cells were examined to verify that they still
possessed two of the most common pluripotency
markers: Oct3/4 and SSEA-4. SSEA-1 (stage-speciﬁc
embryonic antigen 1) was used as a negative test as it
should only be expressed in differentiated cells.
The results are shown in ﬁgure 5. At one week
post-printing there is little observable difference
between the printed cells and the non-printed control
which conﬁrms that all the tested hPSCs remain plur-
ipotent. The Oct3/4 marker levels are lower than the
normal range for pluripotency in the printed RC-10
and RCi-22 while still being acceptable. The RC-6
SSEA-4 printed result is lower than the control but the
results are still positive and they are within an accep-
table range.
3.5. Printed hPSC-derived hepatocytes
HLC’s progressed to day 6 of the differentiation
protocol were used to determine the effect of bioprint-
ing on cell differentiation in terms of hepatic parkers.
Day 6 HLCs were harvested, dissociated into single
cells and printed into the wells of a 12-well plate. After
printing the differentiation protocol was resumed
Figure 3.Agraph to show the post printing viability of hESCs per sample as a function of pressure and nozzle length.
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until day 17 after which the cells were tested for the
presence of albumin and HNF4α, ZO-1 was used to
check themorphology of the cells.
Both hESC- and hiPSC-derived HLCs were bio-
printed and the results are shown in ﬁgure 6.When the
cells were compared to an unprinted control all hepa-
tic markers were expressed indicating that cells can be
printed during the directed differentiation process
without interrupting the differentiation or changing
the lineage of the cells. This is an important result as it
means that these cells can be patterned in three-
dimensions using our bioprinter while differentiating
which will greatly speed up the creation of mini-liver
tissue structures.
3.6. 3DBioprintingwith hydrogel
Sodium alginate solutions with concentrations from
0.1% to 5% were successfully dispensed using the
bioprinter at inlet pressures of 0.1–1 bar. The calcium
solution has a much lower viscosity and should there-
fore be dispensed at much lower pressures in order to
avoid ﬂooding the printed hydrogel structure with
excess calcium solution.
The process of in vivo liver organogenesis occurs in
the developing foregut, when newly speciﬁed hepatic
cells separate from the endodermal sheet and form a
dense 3D structure known as a hepatoblast (liver bud)
[74, 75]. It is hypothesized that arranging the hESC–
HLCs in 3D during the differentiation process may
Figure 4. Flow cytometry data plots showing the numbers of live hiPSCs per samplewith numbers of hESCs per sample for
comparison: ((a) and (b)) hiPSC line RCi-22: (a) control; (b) printed cells; ((c) and (d)) hESC line RC-10: (c) control; (d) printed cells;
(e) aa graph to show the percentages of live hiPSCs per samplewith hESC results for comparison.
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yield more mature hepatocytes than conventional 2D
differentiation. The hESC differentiation protocols are
more efﬁcient and robust than hiPSC protocols there-
fore only hESC-derivedHLCswere printed in 3D.
In order for this technique to be useful for tissue
engineering applications, structures need to be tall
enough to allow cells to interact in a three-dimen-
sional environment. The concentration of alginate
solution was set to 1.5% w/v to improve the mechan-
ical strength of the hydrogel and allow it to support
further layers. Circular structures with a large number
of layers were designed and printed out in the wells of a
multi-well plate to allow the structures to be cultured
post-printing. These resulting structures were photo-
graphed for analysis and are shown inﬁgure 7 below.
These structures were printed out in a matter of
minutes and are strong enough to support their own
weight and the weight of further layers (as seen in
ﬁgure 1(d)). The structures spread slightly, but by
slightly altering the volume ratio, concentrations and
surface properties this spreading can be reduced.
Approximately one hour post-printing one of
the HLC-laden alginate ring structures was exam-
ined using a confocal microscope; the 3D image is
shown in ﬁgure 8(a). Cell viability was calculated to
be 55.5% using the Imaris confocal microscope
software. Cell viability declined over the ﬁrst 24 h
which resulted in low cell numbers for hepatic mar-
ker testing following the 3D differentiation process,
but the viability remained stable for the remainder
Figure 5. FACS results ofmulti-marker pluripotency validation: (a) and (b) hESC line RC-6: (a)non-printed control; (b) printed
results; ((c) and (d)) hESC line RC-10: (c)non-printed control; (d) printed results; ((e) and (f)) hiPSC line RCi-22: (e)non-printed
control; (f) printed results.
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of the differentiation process. At day 23 of the dif-
ferentiation process, the cells in the remaining
structures were harvested and stained for the pre-
sence of hepatic markers. As shown in ﬁgure 8(b),
cells are positive for albumin which demonstrates
their hepatic lineage. The normal time required for
2D differentiation of hPSC-HLCs is 17–24 d. How-
ever, based on the results of albumin secretion in
the medium, we observed the 3D printed cells
have taken longer to reach the maximum albumin
secretion than the 2D control as shown in
ﬁgure 8(c). Interestingly, when analyzing the differ-
ence between 20 and 40 layer printed tube struc-
tures, we noticed close-to proportional increase in
albumin secretion to the number of layers as shown
in ﬁgure 8(d). This indicates that the permeability
of the alginate hydrogel allows nutrition and differ-
entiation reagents to enter the structure and
Figure 6. Fluorescence images of printed hPSC-derived hepatocytes showing hepatocytemarker expression in green: ((a) and (b))
hESC-derivedHLCs (RC-10): (a)non-printed control; (b)printed results; ((c) and (d)) hiPSC-derivedHLCs (RCi-22): (c)non-printed
control; (d) printed results (scale bars 50 μm).
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Figure 7. 3Dprinted alginate ring structures with 40 layers printed into thewells of a 24-well plate with blue dye added for visual
clarity: (a) top view; and (b) side view (scale bar 2 mm).
Figure 8. ((a) and (b)) Fluorescence images of printed hESC-derived hepatocytes: (a) a 3D stack ofHLCs printed in hydrogel, recorded
one hour post-printing showing live cells in green and dead cells in red; (b) 2D cells harvested from the alginate at day 23 showing
albumin expression in green andDAPI in blue (scale bars 100 μm); ((c) and (d)) graphs of albumin secretion at set points during the
directed differentiation process for two 3Dprinted structures with 40 and 20 layers aswell as a 2D control: (c)normalized albumin
secretionwhich shows the 40 layer 3Dprinted structure reaches peak albumin secretion after the 2D control (shownhere at day 21 and
day 19 respectively); (d) a comparison between the absolute albumin secretion of the two 3Dprinted structures which shows that
greater number of printed cells printed leads to higher albumin secretion.
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support 3D differentiation and maturation pro-
cesses of the cells, regardless of the height of the
printed structure.
Research is currently underway including investi-
gations to improve the 3D viability and adjusting the
differentiation protocol that may facilitate higher
albumin secretion. For example, the optimization of
hydrogel formation as well as enhanced cell density
may improve the differentiation process for hPSCs in
3D [21, 76, 77].
4. Conclusions
To the best of our knowledge, this study is the ﬁrst to
demonstrate that hiPS cells can be bioprinted without
adversely affecting their biological functions including
viability and pluripotency. Importantly, we veriﬁed
that our valve-based printing process is gentle enough
to not affect the pluripotency of both hESCs and
hiPSCs. A number of different hPSC lines were
directed to differentiate into HLCs. Cells were printed
during the differentiation process and showed no
differences in hepatocyte marker expression and
similar morphology when compared to a non-printed
control. We previously reported the results of an
investigation into the response of hESCs to the valve-
based printing process. Here we build on that study,
performing a deeper investigation to compare the
response of hiPSCs and hESCs to the printing process
using ﬂow cytometry. The effect of nozzle geometry
was investigated and the effects of nozzle length on the
post-printing viability of cells were recorded; longer
nozzles lower the post-printing viability of the cells.
We printed hESC-derived HLCs in a 3D alginate
matrix and tested for viability and hepatic markers
during the remaining differentiation and they were
found to be hepatic in nature. The ability to bioprint
hPSCs while either maintaining their pluripotency or
directing their differentiation into speciﬁc cell types
will pave the way for producing organs or tissues on
demand from patient speciﬁc cells which could be
used for animal-free drug development and persona-
lizedmedicine.
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